350 руб
Журнал «Технологии живых систем» №4 за 2013 г.
Статья в номере:
Рак яичников и матриксные металлопротеиназы
Ключевые слова: ММП TИMП рак яичников
Авторы:
Д.Н. Кушлинский - хирург-онкогинеколог, ФГБУ «Российский научный центр акушерства, гинекологии и перинатологии им. В.И. Кулакова» МЗ РФ (Москва) И.В. Терешкина - к.м.н., соискатель, кафедра клинической биохимии и лабораторной диагностики, ФПДО ГБОУ ВПО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» МЗ РФ Н.В. Левкина - к.м.н., ст. лаборант, кафедра онкологии, лечебный факультет, ГБОУ ВПО «Первый Московский медицинский университет им. М.И. Сеченова» МЗ РФ. E-mail: n.lev2014@yandex.ru Ю.В. Крюк - к.м.н., ст. лаборант, кафедра клинической биохимии и лабораторной диагностики, ФПДО ГБОУ ВПО «Московский государственный медико-стоматологический университет им. А.И.Евдокимова» МЗ РФ
Аннотация:
Представлены современные данные литературы о роли матриксных металлопротеиназ (ММП) и их ингибиторов (TИMП) при новообразова-ниях яичников, их связи с пролиферативной, инвазивной активностью, неоангиогенезом, способностью к метастазированию и прогнозом заболевания, а также возможности таргетной анти-ММП терапии.
Страницы: 3-18
Список источников

 

  1. Аксель Е.М.Статистика злокачественных новообразований женских половых органов // Опухоли женской репродуктивной системы. 2009. С. 79-80.
  2. Герштейн Е.С., Кушлинский Н.Е. Современные представления о механизмах передачи сигналов факторов роста как основа эффективной молекулярно-наравленной противоопухолевой терапии. // Вопросы биологической, медицинской и фармацевтической химии. 2007. № 1. С. 4-9.
  3. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ (состояние онкологической помощи, заболеваемость и смертность). // Вестник РОНЦ им. Н.Н. Блохина РАМН. 2009. V. 20 (3 (Прил. 1)). С. 52-122.
  4. Жорданиа К.И.Злокачественные новообразования яичников // Энциклопедия клинической онкологии. М.: РОНЦ им. Н.Н. Блохина РАМН. 2004. С. 356-358.
  5. Жорданиа К.И.// Русский медицинский журнал. Онкология. 2002. V. 10 (24). С. 1095-1102.
  6. Жорданиа К.И.Злокачественные эпителиальные  опухоли яичников // Современная онкология. 2000. V. 2 (2). С. 51-55.
  7. Жорданиа К.И., Кушлинский Н.Е., Козаченко В.П. и др.Опухоли яичников // В кн.: Клиническая онкогинекология: Руководство для врачей / под ред. проф В.П. Козаченко. М.: Медицина. 2005. P. 220-269.
  8. Кадагидзе З.Г., Шелепова В.М. Роль опухолеассоциированных антигенов в диагностике онкогинекологических заболеваний // В кн: Клиническая онкогинекология: Руководство для врачей / под ред. проф В.П. Козаченко. М.: Медицина. 2005. С. 49-61.
  9. Кузнецов В.В., Блюменберг А.Г., Лазарева Н.И., Давыдова И.Ю.Опухоли яичников. 2008.
  10. Новикова Е.Г., Ронина Е.А. Особенности эпидемиологии и современные методы диагностики злокачественных опухолей яичников // Гиникология. 1999. № 2. С. 42 - 44.
  11. Тюляндин С.А.Герминогенные опухоли яичников. // Практическая онкология (Герминогенные опухоли). 2006. V. 7(2). С. 63-68.
  12. Урманчеева А.Ф., Мешкова И.Е. Вопросы эпидемиологии и диагностики рака яичников // Практическая  онкология. 2000. № 4. С. 7-13.
  13. Acar A., Onan A., Coskun U. et al. Clinical significance of serum MMP-2 and MMP-7 in patients with ovarian cancer // Med. Oncol. 2008. V. 25(3). P. 279-283.
  14. Adley B.P., Gleason K.J., Yang X.J., Stack M.S. Expression of membrane type 1 matrix metallo­proteinase (MMP-14) in epithelial ovarian cancer: high level expression in clear cell carcinoma // Gynecol. Oncol. 2009. V. 112 (2). P. 319-324.
  15. Australian Institute of Health and Welfare (AIHW) A.A.o.C.R.A. Cancer survival in Australia, 2001. Part1: National summary statistics. // Canberra; 2001 Report No: AIHW CatNo CAN 13. 2001.
  16. Baker A.H., Edwards D.R., Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities // J. Cell Sci. 2002. V. 115 (Pt. 19). P. 3719-3727.
  17. Bast R.C., Jr., Badgwell D., Lu Z. et al. New tumor markers: CA125 and beyond // Int. J. Gynecol. Cancer. 2005. V. 15. Suppl. 3. P. 274-281.
  18. Bast R.C., Jr., Boyer C.M., Jacobs I. et al. Cell growth regulation in epithelial ovarian cancer // Cancer. 1993. V. 71 (4 Suppl). P. 1597-1601.
  19. Belotti D., Calcagno C., Garofalo A. et al. Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion // Mol. Cancer Res. 2008. V. 6(4). P. 525-534.
  20. Belotti D., Paganoni P., Manenti L. et al. Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation // Cancer Res. 2003. V. 63(17). P. 5224-5229.
  21. Brand K., Baker A.H., Perez-Canto A. et al. Treatment of colorectal liver meta-stases by adenoviral transfer of tissue inhibitor of metalloproteinases-2 into the liver tissue // Cancer Res. 2000. V. 60(20). P. 5723-5730.
  22. Cai K.Q., Yang W.L., Capo-Chichi C.D. et al. Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis // Mol. Carcinog. 2007. V. 46 (2). P. 130-143.
  23. Celiker M.Y., Wang M., Atsidaftos E. et al. Inhibition of Wilms\' tumor growth by intramuscular admi-nistration of tissue inhibitor of metallopro-teinases-4 plasmid DNA // Oncogene. 2001. V. 20(32). P. 4337-4343.
  24. Choi J.H., Choi K.C., Auersperg N., Leung P.C. Gonadotropins activate proteolysis and increase invasion through protein kinase A and phospha-tidylinositol 3-kinase pathways in human epithelial ovarian cancer cells // Cancer Res. 2006. V. 66(7). P. 3912-3920.
  25. Davidson B., Goldberg I., Berner A. et al. Expres-sion of membrane-type 1, 2, and 3 matrix metallo­proteinases messenger RNA in ovarian carcinoma cells in serous effusions // Am. J. Clin. Pathol. 2001. V. 115(4). P. 517-524.
  26. Davidson B., Goldberg I., Gotlieb W.H. et al. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian car-cinoma // Clin. Exp. Metastasis. 1999. V. 17(10). P. 799-808.
  27. Davidson B., Goldberg I., Gotlieb W.H. et al. The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma // Mol. Cell Endocrinol. 2002. V. 187 (1-2). P. 39-45.
  28. Demeter A., Sziller I., Csapo Z. et al. Molecular prognostic markers in recurrent and in non-recurrent epithelial ovarian cancer // Anticancer Res. 2005. V. 25 (4). P. 2885-2889.
  29. Deryugina E.I., Quigley J.P. Matrix metallopro-teinases and tumor metastasis // Cancer Meta-stasis Rev. 2006. V. 25 (1). P. 9-34.
  30. Deryugina E.I., Quigley J.P. Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory func-tions // Biochim. Biophys. Acta. 2010. V. 1803 (1). P. 103-120.
  31. Duffy M.J. Proteases as prognostic markers in cancer // Clin. Cancer Res. 1996. V. 2(4). P. 613-618.
  32. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression // Nat. Rev. Cancer. 2002. V. 2(3). P. 161-174.
  33. Ellerbroek S.M., Halbleib J.M., Benavidez M. et al. Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association // Cancer Res. 2001. V. 61(5). P. 1855-1861.
  34. Ellerbroek S.M., Wu Y.I., Overall C.M., Stack M.S. Functional interplay between type I collagen and cell surface matrix metalloproteinase activity // J. Biol. Chem. 2001. V. 276(27). P. 24833-24842.
  35. Furuya M. Analysis of matrix metalloproteinases and related tissue inhibitors in cystic fluids of ovarian tumors // Hokkaido Igaku Zasshi. 1999. V. 74 (2). P. 145-155.
  36. Furuya M., Ishikura H., Kawarada Y. et al. Expression of matrix metalloproteinases and related tissue inhibitors in the cyst fluids of ovarian mucinous neoplasms // Gynecol. Oncol. 2000. V. 78 (2). P. 106-112.
  37. Furuya M., Ishikura H., Nemori R. et al. Clarification of the active gelatinolytic sites in human ovarian neoplasms using in situ zymography // Hum. Pathol. 2001. V. 32 (2). P. 163-168.
  38. Furuya M., Ishikura H., Ogawa Y. et al. Analyses of matrix metalloproteinases and their inhibitors in cyst fluid of serous ovarian tumors // Pathobiology. 2000. V. 68(6). P. 239-244.
  39. Goldman S., Shalev E. MMPS and TIMPS in ovarian physiology and pathophysiology // Front Biosci. 2004. V. 9. P. 2474-2483.
  40. Hu X.X., Li L., Li D.R. et al. Expression of matrix metalloproteinases-9,2,7,and tissue inhibitor of metalloproteinases-1,2,3 mRNA in ovarian tumors and their clinical significance // Ai Zheng. 2004. V. 23 (10). P. 1194-1198.
  41. Hu X.X., Li L., Li D.R., et al. [Inhibitory effects of antisense MMP-9 oligodeoxynucleotides on invasi­veness and adherence of ovarian cancer cells] // Zhonghua Zhong Liu Za Zhi. 2006. V. 28(9). P. 662-665.
  42. Huang L.W., Garrett A.P., Bell D.A. et al. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors // Gynecol. Oncol. 2000. V. 77 (3). P. 369-376.
  43. Jemal A., Murray T., Samuels A. et al. Cancer sta-tistics, 2003 // CA Cancer J. Clin. 2003. V. 53(1). P. 5-26.
  44. Jobling T., Mamers P., Healy D.L. et al. A pros-pective study of inhibin in granulosa cell tumors of the ovary // Gynecol. Oncol. 1994. V. 55 (2). P. 285-289.
  45. Jumper C., Cobos E., Lox C. Determination of the serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in patients with either advanced small-cell lung cancer or non-small-cell lung cancer prior to treatment // Respir. Med. 2004. V. 98 (2). P. 173-177.
  46. Kamat A.A., Fletcher M., Gruman L.M. et al. The clinical relevance of stromal matrix metallo-proteinase expression in ovarian cancer // Clin. Cancer Res. 2006. V. 12 (6). P. 1707-1714.
  47. Kenny H.A., Kaur S., Coussens L.M., Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin // J. Clin. Invest. 2008. V. 118 (4). P. 1367-1379.
  48. Kenny H.A., Lengyel E. MMP-2 functions as an early response protein in ovarian cancer meta-stasis // Cell Cycle. 2009. V. 8(5). P. 683-688.
  49. Kim T.J., Rho S.B., Choi Y.L. et al. High expression of tissue inhibitor of metalloproteinase-2 in serous ovarian carcinomas and the role of this expression in ovarian tumorigenesis // Hum. Pathol. 2006. V. 37 (7). P. 906-913.
  50. Lahav-Baratz S., Kraiem Z., Shiloh H. et al. Decreased expression of tissue inhibitor of matrix metalloproteinases in follicular fluid from women with polycystic ovaries compared with normally ovulating patients undergoing in vitro fertilization // Fertil Steril. 2003. V. 79 (3). P. 567-571.
  51. Lau M.T., Wong A.S., Leung P.C. Gonadotropins Induce Tumor Cell Migration and Invasion by In­creasing Cyclooxygenases Expression and Prosta­glandin E2 Production in Human Ovarian Cancer Cells // Endocrinology. 2010. V. 92. P. 765-767.
  52. Lewandowski K.C., Komorowski J., O\'Callaghan C.J. et al. Increased circulating levels of matrix metalloproteinase-2 and -9 in women with the polycystic ovary syndrome // J. Clin. Endocrinol. Metab. 2006. V. 91 (3). P. 1173-1177.
  53. Lin S.W., Lee M.T., Ke F.C. et al. TGFbeta1 stimulates the secretion of matrix metallopro­teinase 2 (MMP2) and the invasive behavior in human ovarian cancer cells, which is suppressed by MMP inhibitor BB3103 // Clin. Exp. Metastasis. 2000. V. 18 (6). P. 493-499.
  54. Liotta L.A., Tryggvason K., Garbisa S. et al. Metastatic potential correlates with enzymatic deg­radation of basement membrane collagen // Nature. 1980. V. 284 (5751). P. 67-68.
  55. Liu B., Cai L.Y., Lv H.M. et al. Raised serum levels of matrix metalloproteinase-9 in women with polycystic ovary syndrome and its association with insulin-like growth factor binding protein-1 // Gynecol. Endocrinol. 2008. V. 24 (5). P. 285-288.
  56. Lutgendorf S.K., Lamkin D.M., Jennings N.B. et al. Biobehavioral influences on matrix metalloprotei­nase expression in ovarian carcinoma // Clin. Cancer Res. 2008. V. 14 (21). P. 6839-6846.
  57. Maatta M., Santala M., Soini Y. et al. Matrix metalloproteinases 2 and 9 and their tissue in­hibitors in low malignant potential ovarian tumors // Tumour Biol. 2004. V. 25 (4). P. 188-192.
  58. Maatta M., Talvensaari-Mattila A., Turpeenniemi-Hujanen T., Santala M. Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) and their tissue inhibitors (TIMP-1 and TIMP-2) in differential diagnosis between low malignant potential (LMP) and ma­lignant ovarian tumours // Anticancer Res. 2007. V. 27 (4C). P. 2753-2758.
  59. Malemud C.J. Matrix metalloproteinases (MMPs) in health and disease: an overview // Front Biosci. 2006. V. 11. P. 1696-1701.
  60. Manenti L., Paganoni P., Floriani I. et al. Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma // Eur. J. Cancer. 2003. V. 39 (13). P. 1948-1956.
  61. Meinhold-Heerlein I., Bauerschlag D., Zhou Y. et al. An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma // Clin. Cancer Res. 2007. V. 13 (2 Pt 1). P. 458-466.
  62. Moore R.G., Brown A.K., Miller M.C. et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass // Gynecol. Oncol. 2008. V. 108 (2). P. 402-408.
  63. Moore R.G., MacLaughlan S., Bast R.C., Jr. Current state of biomarker development for clinical application in epithelial ovarian cancer // Gynecol. Oncol. 2010. V. 116 (2). P. 240-245.
  64. Moss N.M., Barbolina M.V., Liu Y. et al. Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in I.p. metastatic dissemination // Cancer Res. 2009. V. 69 (17). P. 7121-7129.
  65. Murphy G., Nagase H. Progress in matrix metalloproteinase research // Mol. Aspects Med. 2008. V. 29 (5). P. 290-308.
  66. Nakajima M., Welch D.R., Wynn D.M. et al. Serum and plasma M(r) 92,000 progelatinase levels correlate with spontaneous metastasis of rat 13762NF mammary adenocarcinoma // Cancer Res. 1993. V. 53 (23). P. 5802-5807.
  67. Nam E.J., Yun M.J., Oh Y.T. et al. Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI // Gynecol. Oncol. 2010. V. 116 (3). P. 389-394.
  68. Naylor M.S., Stamp G.W., Davies B.D., Balkwill F.R. Expression and activity of MMPS and their regulators in ovarian cancer // Int. J. Cancer. 1994. V. 58 (1). P. 50-56.
  69. Nelson A.R., Fingleton B., Rothenberg M.L., Matrisian L.M. Matrix metalloproteinases: biologic activity and clinical implications // J. Clin. Oncol. 2000. V. 18 (5). P. 1135-1149.
  70. Nicosia S.V., Bai W., Cheng J.Q. et al. Oncogenic pathways implicated in ovarian epithelial cancer // Hematol. Oncol. Clin. North Am. 2003. V. 17 (4). P. 927-943.
  71. Nikkola J., Vihinen P., Vuoristo M.S. et al. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma // Clin. Cancer Res. 2005. V. 11 (14). P. 5158-5166.
  72. Nishikawa A., Iwasaki M., Akutagawa N. et al. Expression of various matrix proteases and Ets family transcriptional factors in ovarian cancer cell lines: correlation to invasive potential // Gynecol. Oncol. 2000. V. 79 (2). P. 256-263.
  73. Okamoto T., Niu R., Yamada S. Increased expression of tissue inhibitor of metalloproteinase-2 in clear cell carcinoma of the ovary // Mol. Hum. Reprod. 2003. V. 9 (10). P. 569-575.
  74. Ozalp S., Tanir H.M., Yalcin O.T. et al. Prognostic value of matrix metalloproteinase-9 (gelatinase-B) expression in epithelial ovarian tumors // Eur. J. Gynaecol. Oncol. 2003. V. 24 (5). P. 417-420.
  75. Paulsen T., Ree A.H., Kaern J. et al. Expression of matrix metalloproteinase-2 in serous borderline ovarian tumors is associated with noninvasive implant formation // Eur. J. Gynaecol. Oncol. 2007. V. 28 (5). P. 356-363.
  76. Perigny M., Bairati I., Harvey I. et al. Role of immunohistochemical over­expression of matrix metallopro­teinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer // Am. J. Clin. Pathol. 2008. V. 129 (2). P. 226-231.
  77. Ramnath N., Creaven P.J. Matrix metalloproteinase inhibitors // Curr. Oncol. Rep. 2004. V. 6 (2). P. 96-102.
  78. Rauvala M., Puistola U., Turpeenniemi-Hujanen T. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor // Gynecol. Oncol. 2005. V. 99 (3). P. 656-663.
  79. Rauvala M., Turpeenniemi-Hujanen T., Puistola U. The value of sequential serum measurements of gelatinases and tissue inhibitors during chemo­therapy in ovarian cancer // Anticancer Res. 2006. V. 26 (6C). P. 4779-4784.
  80. Ripley D., Tunuguntla R., Susi L., Chegini N. Expression of matrix metalloproteinase-26 and tissue inhibitors of metalloproteinase-3 and -4 in normal ovary and ovarian carcinoma // Int. J. Gynecol. Cancer. 2006. V. 16 (5). P. 1794-1800.
  81. Robertson D.M., Pruysers E., Jobling T. Inhibin as a diagnostic marker for ovarian cancer // Cancer Lett. 2007. V. 249 (1). P. 14-17.
  82. Rodriguez G.C., Haisley C., Hurteau J. et al. Regulation of invasion of epithelial ovarian cancer by transforming growth factor-beta // Gynecol. Oncol. 2001. V. 80 (2). P. 245-253.
  83. Sakata K., Shigemasa K., Nagai N., Ohama K. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary // Int J. Oncol. 2000. V. 17 (4). P. 673-681.
  84. Sawada K., Radjabi A.R., Shinomiya N. et al. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion // Cancer Res. 2007. V. 67 (4). P. 1670-1679.
  85. Schmalfeldt B., Prechtel D., Harting K. et al. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasmi­nogen activator is associated with progression from benign to advanced ovarian cancer // Clin. Cancer Res. 2001. V. 7 (8). P. 2396-2404.
  86. Sedlakova I., Vavrova J., Tosner J., Hanousek L. Lysophosphatidic acid: an ovarian cancer marker // Eur. J. Gynaecol. Oncol. 2008. V. 29 (5). P. 511-514.
  87. Shield K., Riley C., Quinn M.A. et al. Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis // J. Carcinog. 2007. V. 6. P. 11.
  88. Shigemasa K., Tanimoto H., Sakata K. et al. Induction of matrix metalloprotease-7 is common in mucinous ovarian tumors including early stage disease // Med. Oncol. 2000. V. 17 (1). P. 52-58.
  89. Sillanpaa S., Anttila M., Suhonen K. et al. Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metallo­proteinase 2 in epithelial ovarian cancer // Tumour Biol. 2007. V. 28 (5). P. 280-289.
  90. Sillanpaa S., Anttila M., Voutilainen K. et al. Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer // Gynecol. Oncol. 2007. V. 104 (2). P. 296-303.
  91. Sillanpaa S.M., Anttila M.A., Voutilainen K.A. et al. Prognostic significance of matrix metallo­proteinase-7 in epithelial ovarian cancer and its relation to beta-catenin expression // Int. J. Cancer. 2006. V. 119 (8). P. 1792-1799.
  92. Sodek K.L., Ringuette M.J., Brown T.J. MT1-MMP is the critical determinant of matrix degradation and invasion by ovarian cancer cells // Br. J. Cancer. 2007. V. 97 (3). P. 358-367.
  93. Sood A.K., Bhatty R., Kamat A.A. et al. Stress hormone-mediated invasion of ovarian cancer cells // Clin. Cancer Res. 2006. V. 12 (2). P. 369-375.
  94. Sood A.K., Fletcher M.S., Coffin J.E. et al. Functional role of matrix metalloproteinases in ovarian tumor cell plasticity // Am. J. Obstet. Gynecol. 2004. V. 190 (4). P. 899-909.
  95. Symowicz J., Adley B.P., Gleason K.J. et al. Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells // Cancer Res. 2007. V. 67 (5). P. 2030-2039.
  96. Tanimoto H., Underwood L.J., Shigemasa K. et al. The matrix metalloprotease pump-1 (MMP-7, Matrilysin): A candidate marker/target for ovarian cancer detection and treatment // Tumour Biol. 1999. V. 20 (2). P. 88-98.
  97. Torng P.L., Mao T.L., Chan W.Y. et al. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression // Gynecol. Oncol. 2004. V. 92 (2). P. 559-567.
  98. Ulku A.S., Schafer R., Der C.J. Essential role of Raf in Ras transformation and deregulation of matrix me­talloproteinase expression in ovarian epithelial cells // Mol. Cancer Res. 2003. V. 1 (14). P. 1077-1088.
  99. Visintin I., Feng Z., Longton G. et al. Diagnostic markers for early detection of ovarian cancer // Clin. Cancer Res. 2008. V. 14 (4). P. 1065-1072.
  100. Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry // Circ. Res. 2003. V. 92 (8). P. 827-839.
  101. Wang F.Q., Smicun Y., Calluzzo N., Fishman D.A. Inhibition of matrilysin expression by antisense or RNA interference decreases lysophosphatidic acid-induced epithelial ovarian cancer invasion // Mol. Cancer Res. 2006. V. 4 (11). P. 831-841.
  102. Wang F.Q., So J., Reierstad S., Fishman D.A. Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase // Int. J. Cancer. 2005. V. 114 (1). P. 19-31.
  103. Wang F.Q., So J., Reierstad S., Fishman D.A. Vascular endothelial growth factor-regulated ova­rian cancer invasion and migration involves expression and activation of matrix metalloprotei­nases // Int. J. Cancer. 2006. V. 118 (4). P. 879-888.
  104. Webb P.M., Purdie D.M., Grover S. et al. Symptoms and diagnosis of borderline, early and advanced epithelial ovarian cancer // Gynecol. Oncol. 2004. V. 92 (1). P. 232-239.
  105. Westermarck J., Kahari V.M. Regulation of matrix metalloproteinase expression in tumor invasion // FASEB J. 1999. V. 13 (8). P. 781-792.
  106. Wu M., Shi Y., Xi L. et al. Construction of antisense MT1-MMP vector and its inhibitory effects on invasion of human ovarian cancer cells // J. Huazhong Univ. Sci. Technolog. Med. Sci. 2005. V. 25 (6). P. 715-717.
  107. Wu M., Xu G., Xi L. et al. Down-regulation of MT1-MMP expression suppresses tumor cell invasion in metastatic human SW626 ovarian cancer cells // Oncol Rep. 2006. V. 15 (2). P. 501-505.
  108. Wu X., Li H., Kang L. et al. Activated matrix metalloproteinase-2--a potential marker of prognosis for epithelial ovarian cancer // Gynecol Oncol. 2002. V. 84 (1). P. 126-134.
  109. Zhang A., Meng L., Wang Q. et al. Enhanced in vitro invasiveness of ovarian cancer cells through up-regulation of VEGF and induction of MMP-2 // Oncol Rep. 2006. V. 15 (4). P. 831-836.
  110. Zhou H.Y., Wong A.S. Activation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells // Endocrinology. 2006. V. 147 (5). P. 2557-2566.
  111. Zivanovic O., Sima C.S., Iasonos A. et al. Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer // Gynecol. Oncol. 2009. V. 115 (2). P. 209-214.
  112. Zohny S.F., Fayed S.T.Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemo­kine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer // Med. Oncol. 2009. V. 27(4). P.1246-1253.